Mon 12/18/2017 17:30 ET
DJIA24792.20140.460.57%SOLAR24.890.361.45%GOLD1264.607.080.56%Shanghai3136.7734.501.10%
S&P 5002690.1614.260.53%BANKS28.060.250.89%OIL57.270.060.10%Nikkei22420.08417.011.86%
NASDAQ6994.7658.060.83%SEMI99.581.731.74%US/EU1.180.000.33%Futures2695.7513.750.51%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Myomo Inc. - MYO   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add MYO
  
From: SunTzu772 (Rep: 990) reply to SunTzu772Date: 11/29/2017 12:03
Forum: Myomo Inc. - Msg #189Thread #673961096 (Rec: 0)
3.26 back in some down here

----

Myomo, Inc. Reports Third Quarter 2017 Results


----
The third quarter of 2017 marked Myomo’s first full quarter as a publicly traded company. Total revenue for the third quarter increased 165% year over year to $489,000, compared to $184,000 for the third quarter of 2016. Third quarter revenue increased 59% compared with the second quarter of 2017. Gross margin in the third quarter was 75%, up from 58% in the year ago period and from 68% last quarter. For the nine months ended September 30, 2017, total revenue increased 54% to $1,011,000, as compared to $655,000 for the nine months ended September 30, 2016.
----

Paul R. Gudonis, Chairman & CEO of Myomo, commented: “We are pleased to report 165% year over year and 59% sequential revenue growth in the third quarter of 2017. Sales and marketing programs we have established, including MyoPro Centers of Excellence, Ottobock distribution agreement, and next generation MyoPro 2 product line, are paving way for our growth agenda. We are pleased to report positive clinical and patient feedback, facilitating efforts to serve the large, unmet market need to restore function in paralyzed or weakened upper limbs.”

----

https://finance.yahoo.com/news/myomo-inc-reports-third-quarter-211300659.html

----

Myomo Expands MyoPro® Centers of Excellence Program

https://finance.yahoo.com/news/myomo-expands-myopro-centers-excellence-130000249.html



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to SunTzu772 - Msg #170 - 11/03/2017 11:55

Re: 2.64 in down here 3.63... Myomo Enters Canadian Market

----

Myomo Enters Canadian Market

Business Wire November 3, 2017

----

CAMBRIDGE, Mass.--(BUSINESS WIRE)--
----
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Application for a Canadian Medical Device License has been approved by Health Canada. With the license, Myomo and its distribution partner, Ottobock, are now entering the Canadian market for commercial sale of the MyoPro myolelectric arm orthosis (powered brace).
----
MyoPro is the only lightweight wearable device on the market that can help restore substantial functionality in the paralyzed or weakened arms and hands of individuals who have suffered the effects of a stroke, brachial plexus injury (BPI) or other neuromuscular disease or injury. The orthosis senses a patient’s own EMG signals through non-invasive sensors, allowing a patient to perform activities of daily living including feeding themselves, carrying objects and doing household tasks, and many are able to return to work.
----
“MyoPro is an exciting device and we are enthusiastic about providing this technology to service the unmet needs of patients in Canada,” said Chris Nolan, Vice President, Orthotics, Ottobock North America. Ottobock is the global market leader in technical orthopedics and prosthetics (O&P).
----
Stroke and BPI are the conditions most frequently helped by MyoPro. According to OntarioStrokeNetwork.ca, stroke is the leading cause of adult disability in Canada, with 426,000 Canadians living with the effects of stroke. Each year 50,000 new patients survive stroke and are left living with some degree of impairment. Often, these impairments include a weakened or paralyzed arm that might be helped with MyoPro.
----
Myomo launched its next-generation MyoPro orthosis in June 2017, extending the capabilities of the previous device with significant enhancements, including interchangeable, extended-life rechargeable batteries for continuous daily use. In July, the Company obtained the CE mark, enabling it to enter the European market.
----
"Gaining approval to market MyoPro in Canada increases the base of patients who may now be able to perform activities of daily living despite losing function in an arm,” said Paul R. Gudonis, Chairman and CEO of Myomo. “Additionally, we are pleased to extend our relationship with Ottobock to help us broaden distribution of the MyoPro product line.”
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreMYO: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add MYO
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.